Tarcocimab Tedromer Shows Promise for Diabetic Retinopathy in GLOW1

The anti-VEGF agent tarcocimab significantly improved diabetic retinopathy severity score compared with SHAM in a phase 3 study.

Related Keywords

,Austin Retina Associates Robertw Wong ,Association For Research ,Austin Retina Associates ,Diabetic Retinopathy ,Vegf ,Tarcocimab ,